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Abstract
Background: Prompt use of an effective anti-malarial drug is essential for controlling malaria and its adverse
effects in pregnancy. The World Health Organization recommends an artemisinin-based combination therapy as
the first-line treatment of uncomplicated malaria in the second and third trimesters of pregnancy. The study
objective was to determine the degree to which presumed episodes of uncomplicated symptomatic malaria in
pregnancy were treated with a recommended anti-malarial regimen in a region of Uganda.
Methods: Utilizing a population-based random sample, we interviewed women living in Jinja, Uganda who had
been pregnant in the past year.
Results: Self-reported malaria during the index pregnancy was reported among 67% (n = 334) of the 500
participants. Among the 637 self-reported episodes of malaria, an anti-malarial drug was used for treatment in 85%
of the episodes. Use of a currently recommended treatment in the first trimester was uncommon (5.6%). A
contraindicated anti-malarial drug (sulphadoxine-pyrimethamine and/or artemether-lumefantrine) was involved in
70% of first trimester episodes. Recommended anti-malarials were used according to the guidelines in only 30.1%
of all second and third trimester episodes.
Conclusions: Self-reported malaria was extremely common in this population and adherence to treatment
guidelines for the management of malaria in pregnancy was poor. Use of artemether-lumefantrine combined with
non-recommended anti-malarials was common practice. Overuse of anti-malarial drugs, especially ones that are no
longer recommended, undermines malaria control efforts by fueling the spread of drug resistance and delaying
appropriate treatment of non-malarial febrile illnesses. Improved diagnostic capacity is essential to ultimately
improving the management of malaria-like symptoms during pregnancy and appropriate use of currently available
anti-malarials.
Background
The deleterious consequences of malaria infection dur-
ing pregnancy for both the mother and her fetus have
been widely reported [1-4]. The current World Health
Organization (WHO) guidelines for the treatment of
uncomplicated malaria in pregnancy recommend an
artemisinin-based combination therapy (ACT) as the
first-line treatment in the second and third trimesters of
pregnancy [5]. Artemisinins are contraindicated during
the first trimester of pregnancy due to embryo-foetal
toxicity observed in studies of rats and rabbits [6-8] and
limited safety data of early pregnancy use in humans
[9,10]. However, the WHO does recommend first trime-
s t e ru s eo fA C Ti ft h et r e a tment is believed to be life-
saving for the mother and other available anti-malarial
drugs are considered unsuitable. Oral quinine plus clin-
damycin for seven days (or quinine monotherapy if clin-
damycin is not available) is the recommended first-line
treatment in the first trimester of pregnancy for uncom-
plicated malaria [5]. Treatment with oral quinine is gen-
erally believed not to be toxic to the foetus, irrespective
of trimester of use [5], although data are limited
[5,9,11,12]. Clindamycin is often not affordable or avail-
able in most malaria endemic countries, and so quinine
monotherapy is more common [12]. While chloroquine
and sulphadoxine-pyrimethamine (SP) monotherapy are
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treatment of uncomplicated falciparum malaria because
of high levels of parasite resistance, their use remains
commonplace [13,14]. Chloroquine is believed to be safe
for use in all trimesters of pregnancy [9,10,15]. SP, a
folic acid antagonist, is contraindicated during the first
trimester of pregnancy because of the potential risk of
cardiac anomalies and neural tube defects [10]; however,
no association between SP exposure in early pregnancy
and increased risk of congenital malformations has been
reported [15].
In Uganda, malaria is thought to be the leading cause
of morbidity and mortality, and accounts for almost half
of all in-patient deaths among children less than five
years of age [16]. The prevalence of placental malaria
(based on PCR) was estimated at 26% for HIV unin-
fected women prescribed intermittent preventive treat-
ment with SP (IPTp-SP) and 19% for HIV infected
women prescribed daily trimethoprim-sulphamethoxa-
zole [17]. The Ugandan Ministry of Health (MOH)
recommends use of microscopy or rapid antigen testing
for the diagnosis of malaria in pregnant women with
symptoms of uncomplicated malaria [18]. However,
diagnostic equipment and/or a trained technician are
often unavailable in rural settings, resulting in a pre-
sumptive diagnosis of malaria based on clinical symp-
toms. Uncomplicated malaria generally presents with
fever, malaise, and other non-specific symptoms; distin-
guishing malaria from other febrile illnesses based on
clinical presentation is challenging [19-23]. Presumptive
treatment of malaria based on fever occurs commonly,
leading to overuse of anti-malarial drugs and delays in
seeking treatment for other febrile illnesses [20,24-27].
In Uganda, artemether-lumefantrine (AL), an ACT, is
the first-line recommended treatment for uncomplicated
malaria. While the Ugandan MOH changed their policy
regarding the treatment of uncomplicated malaria in
pregnancy from chloroquine plus SP to ACT in 2004
based on the WHO recommendations[18], this policy
was not implemented until 2006. During the first half of
2006, all government, private, and not-for-profit health
care facilities received AL free-of-charge [28]. These
supplies were followed by in-service trainings and the
provision of wall-charts [28]. AL was also meant to
replace chloroquine plus SP in the national home-based
management of fever program. However, since 2006,
national shortages of AL have challenged the implemen-
tation of this policy and proper treatment of malaria in
Uganda [28-30].
The purpose of the present analysis was to determine
the degree to which presumed episodes of uncompli-
cated symptomatic malaria in pregnancy were treated
with a recommended anti-malarial regimen in a region
of Uganda.
Methods
Selection of study participants
Between November, 2008 and January, 2009, home-
based interviews were conducted among a simple ran-
dom sample of 500 female residents of Kibibi and
Namizi parishes in Budondo-sub county of Jinja District,
Uganda, to determine patterns of self-reported malaria
episodes and self-reported anti-malarial drug use during
pregnancy. The parent study ascertained use of insecti-
cide treated nets (ITNs) and intermittent presumptive
therapy (IPTp) with SP during pregnancy, as well as
possible factors associated with use. Women who had a
pregnancy within the past 12 months that lasted until at
least the third trimester, regardless of pregnancy out-
come, between the ages of 15 and 49 years, were eligible
to participate. Details of the study population and pro-
cedures have been described elsewhere [31].
Study site
Sampling was based on census data completed in
November 2008 by the Ugandan Malaria Surveillance
Project. Namizi and Kibibi parishes are comprised of
21,681 residents living among 16 rural and peri-urban vil-
lages, of whom 4,654 were females aged 15-49 years, and
867 of these women reported having been pregnant in
the previous 12 months. One public health center that
provides antenatal care is located in each parish; Kibibi
has a level II facility and Namizi has a level IV facility.
The primary economic activity in this area is farming,
with sugar cane and coffee being the main cash crops.
The average annual entomological inoculation rate in
Jinja is 6 infective bites per person per year [32]. Malaria
transmission in this area is considered meso-endemic,
defined by transmission occurring throughout the year
with peaks during two rainy seasons. A cross-sectional
parasitological survey identified a prevalence of the Plas-
modium falciparum parasite of 15% among children 1-9
years of age in 1999 [33].
Administration of the survey
A pregnancy history calendar was generated for each
woman to record episodes of self-reported malaria, any
anti-malarial use during pregnancy, and antenatal care
(ANC) visits. Additionally, when asking specifically about
SP and AL, women were shown photographs of SP and
AL packaging and the corresponding tablets for the most
common formulations of these drugs available in the area.
In this setting, non-artemisinin anti-malarials were
available from privately owned drug shops and other
non-clinical sources, making presumptive self-treatment
unaccompanied by medical consultation possible. Because
one of the aims of the project was to identify factors
associated with use of IPTp with SP, for each ANC visit
the woman attended, she was asked if SP was offered and
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anti-malarial medications (e.g. health center, drug shop,
community health worker, friend) was not ascertained.
Gestational age by trimester was estimated by subtracting
an average pregnancy length of 40 weeks from the child’s
date of birth unless other information was provided to
suggest the pregnancy was of a shorter or longer dura-
tion. This information allowed for the identification of
the calendar month associated with each trimester of
pregnancy.
Data management
A pre-tested interviewer-administered structured ques-
tionnaire was used to collect participant responses. The
questionnaire ascertained information on socio-demo-
graphic characteristics, socio-cultural factors, obstetric
history, knowledge and attitude about malaria, antenatal
clinic use, use of ITNs and IPTp, self-reported episodes
of malaria and anti-malarial drug use. Wherever possible,
questions were taken from those used in large interna-
tional surveys, including the Uganda Demographic Health
Survey, and the Malaria Indicator Survey [34,35]. The
questionnaire was translated from English to Lusoga.
Definitions
Self-reported malaria was ascertained by asking the
woman if she believed she was ever sick with malaria
during the index pregnancy. If a study subject reported
yes, then the timing and treatment of each presumed
episode was recorded. Because the policy of presumptive
treatment of malaria based on clinical symptoms is
common in this area, and the public health centers in
these parishes lack diagnostic equipment, it was deter-
mined that soliciting additional information regarding a
health provider’s diagnosis or laboratory test would not
greatly improve the validity of this assessment. All possi-
ble treatments utilized were recorded for each episode
and were captured as: AL, SP, quinine, chloroquine,
paracetamol, herbs, no treatment, or other if none of
the above. Treatments were compared to anti-malarials
currently recommended by the Ugandan MOH, strati-
fied by first and second/third trimesters of pregnancy.
Current recommendations were enacted as policy in
2005, and pregnancies included in the study occurred
between 2007 and 2009.
Statistical analysis
Analyses were performed using Stata version 11.0 (Col-
lege Station, Texas, USA). Patterns of use of anti-malar-
ials drugs in response to self-reported episodes of malaria
were determined and reported as frequencies. Primary
analyses calculated the proportion of self-reported malaria
episodes treated with a WHO recommended drug regi-
men, stratified by trimester of pregnancy.
Ethical approval
The study was approved by the Makerere University
Research and Ethics Committee, the Uganda National
Council for Science and Technology, and the University
of Washington Human Subjects Division. All partici-
pants provided written informed consent.
Results
Characteristics of the study population
Six hundred twenty nine households were visited
between November 2008 and January 2009 to identify
500 eligible women. All of the potential study subjects
agreed to participate. Eligibility and participation of
study subjects have been published elsewhere [31]. The
demographic characteristics of the study population are
shown in Table 1. Stillbirth occurred in seven of the
index pregnancies, and the remaining pregnancies ended
in a live birth. Nearly all women (99%) attended ANC at
least 1 time, 95% with 2 or more visits, 73% had 3 or
more visits, and 34% with the recommended four
or more visits during pregnancy. The mean number of
ANC visits was 3.2, and 86% of women initiated ANC
during the 1
st or 2
nd trimester.
The self-perceived risk of malaria during pregnancy
was high, with 70% of women responding they were
specifically worried about getting sick with malaria dur-
ing their most recent pregnancy. Miscarriage/stillbirth
was the most feared consequence of malaria in preg-
nancy reported by women (50%), followed by maternal
death (16%), and the baby being adversely affected
(12%).
Occurrence of self-reported malaria
Self-reported malaria during the index pregnancy was
reported by 67% (n = 334) of participants (Table 2).
Multiple self-reported malaria episodes were also com-
mon, with 37% of women reporting two or more
malaria episodes. A total of 637 episodes were reported
in the cohort. Among women with self-reported malaria,
the first reported malaria episode occurred most fre-
quently during the 2
nd trimester (46%), followed by the
1
st trimester (36%).
Self-reported use of anti-malarials during pregnancy
Among women with self-reported malaria, 94% reported
using an anti-malarial drug at least once to treat malaria
during the index pregnancy. This represents 63% of all
women interviewed.
Among the 637 self-reported episodes of malaria during
the index pregnancy, an anti-malarial drug was used for
treatment in 85% of the episodes. Use of anti-malarials
was stratified by trimester of pregnancy and categorized
by currently recommended treatments (Table 3). Use of a
currently recommended treatment in the first trimester
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were treated with quinine. A contraindicated anti-malarial
drug (SP and/or AL) was involved in 70% of first trime-
ster episodes. Use of AL alone or in conjunction with
another anti-malarial was the most common regimen in
the first trimester (42%), followed by SP monotherapy
(23%). A stratified analysis showed no difference between
the proportion of women using a recommended treat-
ment in the first trimester between primigravid and mul-
tigravid women (p = 0.4).
Half of all second and third trimester episodes (240/
478) were treated with a currently recommended anti-
malarial (AL or quinine). However 40% of episodes trea-
ted with a recommended anti-malarial (96/240) were
also treated with an additional, non-recommended anti-
malarial, either before, after, or concurrently with the
recommended anti-malarials (Table 3). Recommended
anti-malarials were used according to the guidelines in
only 30.1% of all second and third trimester episodes.
Precise data on the sequence of anti-malarials during
treatment of individual episodes of self-reported illness
are not available. SP, which was not recommended for
treatment of symptomatic malaria owing to widespread
drug resistance, was used alone or in combination in 33%
of the episodes. There was no difference between the
proportion of women using a recommended treatment in
the second/third trimester of pregnancy between primi-
gravid and multigravid women (p = 0.6).
Discussion
These results suggest that self-reported malaria was
extremely common in this population; nearly two-thirds
of women experienced at least one episode of illness
during their most recent pregnancy. Adherence to treat-
ment guidelines for management of malaria in preg-
nancy was poor. Almost all self-reported malaria
episodes occurring during the first trimester of preg-
nancy were treated with a non-recommended regimen
and 70% included a drug that is contraindicated in preg-
nancy. In second and third trimesters, only one-third of
episodes were treated with an anti-malarial regimen
according to the guidelines. Use of AL combined with
non-recommended anti-malarials was common practice.
To minimize adverse pregnancy outcomes related to
malaria, timely and effective treatment is essential. How-
ever, only a limited number of anti-malarial drugs avail-
able are deemed safe for use in pregnancy. The lack of
Table 1 Characteristics of the study population
Characteristic Total Population
n = 500
Age (years); n (%)
≤18 years 50 (10.0)
19 - 24 years 204 (40.8)
25 - 34 years 182 (36.4)
≥35 years 64 (12.8)
Married; n (%) 451 (90.2)
Education; n (%)
None 34 (6.8)
Primary 350 (70.0)
Secondary/Postsecondary 116 (23.2)
Religion; n (%)
Christian-based 305 (61.0)
Muslim 195 (39.0)
Village type; n (%)
Rural 372 (74.4)
Peri-Urban 128 (25.6)
Number of births; n (%)
1 111 (22.2)
2-3 152 (30.4)
4-5 111 (22.2)
≥6 126 (25.2)
History of miscarriage; n (%) 85 (17.0)
History of stillbirth; n (%) 23 (4.6)
Birth location; n (%)
Health facility 367 (73.4)
Home 81 (16.2)
Other 52 (10.4)
Knowledge of malaria score; n (%)
High 292 (58.4)
Low 208 (41.6)
# ANC visits; n (%)
0 6 (1.2)
1 23 (4.6)
2 106 (21.2)
3 195 (39.0)
≥4 170 (34.0)
Month of ANC initiation; mean (sd) 4.8 (1.6)
Walking time to nearest ANC, minutes; mean (sd) 69 (44.2)
Waiting time at ANC, minutes; mean (sd) 58 (47.7)
Table 2 Self-reported malaria during pregnancy
Characteristic TOTAL (n = 500
women)
Women with self-reported malaria during index
pregnancy; n (%)
334 (66.8)
Number of self-reported malaria episodes per
woman; mean (sd)
1.3 (1.2)
0 episode; n (%) 166 (33.2)
1 episode; n (%) 149 (29.8)
2 episodes; n (%) 95 (19.0)
3 episodes; n (%) 67 (13.4)
4 episodes; n (%) 18 (3.6)
5 episodes; n (%) 5 (1.0)
Total number of self-reported malaria episodes
during index pregnancy; n
637
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nancy is a considerable problem that is exacerbated
for malaria episodes occurring in the first trimester as
even fewer drugs are recommended during this embryo-
sensitive period. Use of oral quinine is particularly
problematic considering its marked side-effects, poor
adherence, and a long complicated treatment course
requiring a dose be taken every 8 hours for 7 days
[10,12,36,37]. Furthermore, P. falciparum resistance to
quinine has been reported in Southeast Asia, which may
eventually limit the effectiveness of this regimen [38].
Therefore, first trimester alternatives are needed. Cur-
rently, ACT is contraindicated in the first trimester due
to safety concerns for potential teratogenicity based on
the severe embryo-fetal toxicity observed in rats and
rabbits [6-9]. Recent modeling suggests the probability
is 12% that an embryo will encounter an inadvertent
exposure to artemisinins during the embryo-sensitive
period (between week four and ten of gestation) in areas
where adults receive on average one three-day treatment
with an ACT per year [39]. Monitoring inadvertent and
intended first trimester exposures to ACT using phar-
macovigilance systems such as pregnancy exposure
registries, may eventually provide enough safety evi-
dence in humans to warrant their use in the first trime-
ster [40]. The absence of adequate safety data, especially
in the first trimester, is an important obstacle to malaria
control in pregnancy [41].
Efficacy data from a recent randomized trial conducted
on the Thai-Burmese border reported that 63.4% (95%
CI: 46.9%, 77.4%) of pregnant women with symptomatic
uncomplicated P. falciparum malaria during the second
or third trimesters who were treated with a supervised
7-day course of quinine monotherapy were cured, based
on polymerase chain reaction corrected parasite clearance
at day 63 of follow-up or delivery [42]; this was consider-
ably lower than the proportion of cures in women treated
with three days of artesunate-atovaquone-proguanil
(94.9%; 95% CI: 81.37%, 99.11%). An earlier randomized
trial, comparing artesunate versus quinine plus clindamy-
cin for the treatment of uncomplicated P. falciparum
malaria by the same team in the same area, reported no
difference in efficacy with 100% of the women in each
arm cured [43]. Safe and effective anti-malarial use after
the first trimester of pregnancy is limited to ACT in
most geographic areas, although the available safety data
are limited to 1,500 pregnancies exposed to artemisinin
compounds in the 2
nd and 3
rd trimesters of pregnancy; in
these pregnancies there were no adverse events reported
for the mother or the fetus [5,9,44-46].
Table 3 Proportion of self-reported treated malaria
episodes in which an anti-malarial currently
recommended by the Ugandan MOH was used, by
trimester of pregnancy
1
st Trimester TOTAL
(n = 126
episodes*)
(95% CI)
+
Currently recommended
Quinine monotherapy; n (%) 7 (5.6) (2.5, 10.7)
Not currently recommended 119 (94.4) (89.3,
97.5)
SP monotherapy; n (%) 29 (23.0)
Chloroquine monotherapy; n (%) 18 (14.3)
SP+Chloroquine; n (%) 6 (4.8)
Any AL; n (%) 53 (42.1)
AL alone; n 26
AL +1 other anti-malarial
1;n 2 1
AL + 2 or more other anti-malarials
2;n 6
Other; n (%) 13 (10.3)
2
nd or 3
rd Trimester TOTAL
(n = 478
episodes*)
Currently recommended 144 (30.1) (26.1,
34.3)
AL alone; n (%) 113 (23.6)
Quinine monotherapy; n (%) 28 (5.9)
AL + quinine** 3 (0.6)
Not currently recommended 334 (69.9) (65.6,
73.9)
SP monotherapy; n (%) 132 (27.6)
AL +1 other anti-malarial
3; n 78 (16.3)
Chloroquine monotherapy; n (%) 31 (6.5)
SP+Chloroquine; n (%) 23 (4.8)
AL + 2 or more other anti-malarials
4; n 13 (2.7)
SP+Quinine 5 (1.1)
Other; n (%) 52 (10.9)
Any use of a currently recommended
anti-malarial***; n (%)
240 (50.2) (45.7,
54.7)
Any use of AL; n (%) 207 (43.3)
Any use of quinine; n (%) 33 (6.9)
AL: Artemether-lumefantrine
SP: Sulphadoxine-pyrimethamine
+95% Confidence Interval around the proportion
*Excludes 33 episodes that were not treated; 1
st trimester = 8 episodes; 2
nd
trimester = 25 episodes
**Possibly correct depending on clinical circumstances
***Includes use of recommended drug combined with a non-recommended
drug
1AL plus: SP (n = 16); Chloroquine (n = 3); Quinine (n = 2)
2AL plus: SP & Chloroquine (n = 4); SP & Quinine (n = 1); SP & Chloroquine &
Quinine (n = 1)
3AL plus: SP (n = 71); Chloroquine (n = 7)
4AL plus: SP & Chloroquine (n = 11); SP & Quinine (n = 2)
Sangaré et al. Malaria Journal 2011, 10:152
http://www.malariajournal.com/content/10/1/152
Page 5 of 8When the symptomatic patient is indeed parasitaemic,
continued use of ineffective drugs may select for drug
resistant strains [47]. The extent of the problem of con-
tinued use of ineffective anti-malarials was demonstrated
in our population, in which 44% of all self-reported
malaria episodes were treated using SP and/or chloro-
quine. Anti-malarial drug-efficacy studies conducted in
Jinja between December 2002 and May 2004 reported a
risk of treatment failure of 50% for SP plus chloroquine
among children aged six months to five years with
uncomplicated malaria [48]. Women receiving SP for
treatment of malaria in Jinja are at a high risk of treat-
ment failure, and subsequent morbidities associated with
severe disease.
The most recent guidelines for the treatment of
malaria from WHO recommend that, in all settings,
clinical suspicion of malaria should be confirmed with a
parasitological diagnosis, except in places where parasi-
tological diagnosis is not possible [5]. However, in most
parts of Africa where malaria is endemic, parasitological
diagnosis is indeed not possible, and so presumptive
treatment continues. Considering that malaria typically
presents with non-specific symptoms of fever and
malaise that are indistinguishable from several other feb-
rile illnesses common in the same areas, this practice of
empirical treatment results in substantial overuse of
anti-malarial drugs [20,24-27] and often delays the diag-
nosis of other febrile illnesses leading to poor clinical
outcomes and heightened mortality [13,47]. A recent
study from Mozambique of pregnant women seeking
care for malaria-like symptoms found only 27% of
women with fever were parasitaemic [24]. These data
are similar to other studies conducted in adult and child
populations in Africa reporting only 24-32% of patients
with malaria-like symptoms had malaria, defined by
fever with parasitaemia [25,26,49]. The lack of safety
data on most anti-malarials recommended for use in
pregnancy, particularly for first trimester drug exposures
when organogenesis occurs [5,9,10,50], highlights the
importance of limiting the use of anti-malarial drugs
during pregnancy to women whose symptoms are
caused by malaria. With the advent of rapid diagnostic
testing (RDTs), there is hope that access to parasitologi-
cally-based diagnoses will improve, leading to an even-
tual decrease in overuse of anti-malarials and drug
resistance. However, even in clinics where RDTs are
available, health workers persist in giving anti-malarials
despite negative results [27,51], highlighting the strength
of the widespread belief that fever equals malaria and
lack of clinical capacity to identify alternative diagnoses.
Dedicated resources and political commitment will be
needed to expand use and acceptance of RDTs, but ulti-
mately this technology has the potential to result in a
cost-savings by avoiding use of expensive ACT-based
treatments on people who do not have malaria [52]. It
was recently estimated that for every billion dollars in
subsidy for anti-malarial drugs, around $500 to $900
million dollars are spent on treatments for people who
do not have malaria [52].
This study has several limitations. Data on parasitolo-
gically confirmed cases of malaria were unavailable and,
therefore, we were unable to distinguish which women
had malaria and which ones did not. Data on specific
symptoms were also unavailable and therefore uncom-
plicated cases could not be distinguished from severe
cases, and so we were unable to determine which cases
could be exempted from the recommendations that are
based on uncomplicated malaria. The location where
anti-malarial drugs other than SP came from was not
ascertained and, therefore, the extent to which self-treat-
ment occurred in this population is not known. The dis-
pensing of AL was expected to be limited to health
facilities due to the higher cost associated with this
medication and the general lack of availability of AL in
the private sector. Among women who used more than
one anti-malarial per episode of malaria, it is unknown
if the same provider prescribed the drugs for each epi-
sode, or if this represents women seeking care from
multiple providers, or if self-treating with serial drugs
from multiple shops was occurring. Furthermore, the
availability of an appropriate first-line anti-malarial
treatment in the health facility at the time the woman
received an alternate treatment is unknown. Therefore,
caution is needed when interpreting these results in
relation to health providers. Women with more severe
malaria-like symptoms may have been more likely to
recall the details of this event. However, considering the
majority of women believed they had malaria at least
once during the index pregnancy, recall bias is unlikely
to be significant. Women did not appear to have pro-
blems to recall use or timing of anti-malarial drugs dur-
ing pregnancy. This may be expected considering there
are only a limited number of drugs available for the
treatment of malaria in pregnancy, and that women are
quite experienced with the treatment of malaria based
on the high burden of disease in this community. The
process of gestational age estimation may have resulted
in non-differential misclassification of trimester of anti-
malarial use making frequencies equally as likely to be
under-estimated in each trimester.
To improve recall, interviews were assisted with a
pregnancy history calendar in which each pregnancy
was mapped out over time on the calendar to record
episodes of self-reported malaria, any use of SP or other
anti-malarials during pregnancy, and ANC visits. We
sought to improve the reliability of data related to anti-
malarial drug use in response to self-reported episodes
of malaria by asking multiple questions related to each
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about SP and AL, we showed women photographs of SP
and AL packaging and the corresponding tablets for the
most common formulations available in the area. As
previously reported, the reliability of self-report of SP
use was verified using ANC cards [31]. The concordance
between self-reported SP doses and ANC card was high
(Pearson’s rho = 0.93). In an attempt to decrease mis-
classification between SP used for IPTp and SP used as
treatment, women were asked if they believed they were
sick with malaria at the time they took each dose of SP.
Conclusions
Overuse of anti-malarial drugs, especially ones that are
no longer recommended, undermines malaria control
efforts by fueling the spread of drug resistance and
delaying appropriate treatment of non-malarial febrile
illnesses. Unnecessary exposures to anti-malarials in
pregnancy are particularly of concern given the lack of
human safety data on these drugs. In addition to inten-
sified measures to reduce malaria transmission,
improved diagnostic capacity is essential to ultimately
improving the management of malaria-like symptoms
during pregnancy and appropriate use of currently avail-
able anti-malarials. However, improving diagnostic capa-
city will require additional resources and changes to the
existing health care infrastructure.
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